comparemela.com
  1. Home
  2. Live Updates
  3. Clinical Oncology Volume - Breaking News

Latest Breaking News On - Clinical oncology volume - Page 1 : comparemela.com

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab for G/GEJ Cancer at ASCO 2024

BioPharma

Transcenta holding limitedHolding limitedClinical oncology volume

Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

/PRNewswire/ Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities.

United statesLos angelesProduct development centerPrnewswire transcenta holding limitedTranscenta immune tolerance breaking technologyClinical development centers in princetonGroup headquartersTranslational research centerHolding limitedClinical oncology volumeImmune tolerance breaking technologyOrphan drug designationManufacturing facilityClinical development centersExternal partnering centerSuzhou industrial

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.